Novartis spinout resTORbio reverse merges with T cell biotech after big PhIII failure
The end of their lead program will, it turns out, spell the end for Novartis spinout resTORbio.
Shares for the once well-funded anti-aging biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
